{"id":2058,"date":"2003-05-01T12:09:00","date_gmt":"2003-05-01T10:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure"},"modified":"2003-05-01T12:09:00","modified_gmt":"2003-05-01T10:09:00","slug":"hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/","title":{"rendered":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure"},"content":{"rendered":"<p>Bei manchen Patienten ist die Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure (ASS) sehr gering, so da\u00df sie dadurch kaum vor thrombotischen Komplikationen gesch\u00fctzt werden. Es gibt Hinweise daf\u00fcr, da\u00df eine Hyperlipid\u00e4mie zu dieser ASS-Resistenz beitragen kann. Aus diesem Grund f\u00fchrten M. Friend et al. aus den USA eine Pilotstudie durch, in die 56 Patienten (72% M\u00e4nner) [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bei manchen Patienten ist die Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure (ASS) sehr gering, so da\u00df sie dadurch kaum vor thrombotischen Komplikationen gesch\u00fctzt werden. Es gibt Hinweise daf\u00fcr, da\u00df eine Hyperlipid\u00e4mie zu dieser ASS-Resistenz beitragen kann. Aus diesem Grund f\u00fchrten M. Friend et al. aus den USA eine Pilotstudie durch, in die 56 Patienten (72% M\u00e4nner) [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[128,2195,129,5277,106],"class_list":["post-2058","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-ass","tag-azetylsalizylsaeure","tag-hyperlipidaemie","tag-thrombozytenaggregationshemmer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Bei manchen Patienten ist die Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure (ASS) sehr gering, so da\u00df sie dadurch kaum vor thrombotischen Komplikationen gesch\u00fctzt werden. Es gibt Hinweise daf\u00fcr, da\u00df eine Hyperlipid\u00e4mie zu dieser ASS-Resistenz beitragen kann. Aus diesem Grund f\u00fchrten M. Friend et al. aus den USA eine Pilotstudie durch, in die 56 Patienten (72% M\u00e4nner) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2003-05-01T10:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure\",\"datePublished\":\"2003-05-01T10:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/\"},\"wordCount\":380,\"keywords\":[\"Acetylsalicyls\u00e4ure\",\"ASS\",\"Azetylsalizyls\u00e4ure\",\"Hyperlipid\u00e4mie\",\"Thrombozytenaggregationshemmer\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/\",\"name\":\"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2003-05-01T10:09:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/","og_locale":"de_DE","og_type":"article","og_title":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure - Der Arzneimittelbrief","og_description":"Bei manchen Patienten ist die Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure (ASS) sehr gering, so da\u00df sie dadurch kaum vor thrombotischen Komplikationen gesch\u00fctzt werden. Es gibt Hinweise daf\u00fcr, da\u00df eine Hyperlipid\u00e4mie zu dieser ASS-Resistenz beitragen kann. Aus diesem Grund f\u00fchrten M. Friend et al. aus den USA eine Pilotstudie durch, in die 56 Patienten (72% M\u00e4nner) [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2003-05-01T10:09:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure","datePublished":"2003-05-01T10:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/"},"wordCount":380,"keywords":["Acetylsalicyls\u00e4ure","ASS","Azetylsalizyls\u00e4ure","Hyperlipid\u00e4mie","Thrombozytenaggregationshemmer"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/","name":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2003-05-01T10:09:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hyperlipidaemie-behindert-hemmung-der-plaettchenaggregation-durch-azetylsalizylsaeure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Hyperlipid\u00e4mie behindert Hemmung der Pl\u00e4ttchenaggregation durch Azetylsalizyls\u00e4ure"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2058"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2058\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}